Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. by Lu, Q. et al.
Pharmacokinetics and safety of panobacumab: specific adjunctive
immunotherapy in critical patients with nosocomial
Pseudomonas aeruginosa O11 pneumonia
Qin Lu1†, Jean-Jacques Rouby1†, Pierre-Franc¸ois Laterre2*, Philippe Eggimann3, Anthony Dugard4,
Evangelos J. Giamarellos-Bourboulis5, Emanuelle Mercier6, Jorge Garbino7, Charles-Edouard Luyt8,
Jean Chastre8, Violetta Georgescu-Kyburz9, Michael P. Rudolf9, Verena Gafner9, Hedvika Lazar9, Holger Koch9,
Antonio Perez9, Stefanie D. Kra¨mer10 and Michael Tamm11
1Multidisciplinary Intensive Care Unit, Department of Anesthesiology, La Pitie´-Salpeˆtrie`re Hospital, Assistance Publique Hoˆpitaux de Paris,
UPMC Paris 6, France; 2Intensive Care Unit, St Luc University Hospital, UCL, Brussels, Belgium; 3Centre Hospitalier Universitaire Vaudois,
Lausanne, Switzerland; 4ICU, CIC-P 0801 Inserm, CHU Dupuytren, Limoges, France; 54th Department of Internal Medicine, University of
Athens, Medical School, Greece; 6Hoˆpital Bretonneau, Tours, France; 7University Hospitals of Geneva, Geneva, Switzerland; 8Medical
Intensive Care Unit, La Pitie´-Salpeˆtrie`re Hospital, Assistance Publique Hoˆpitaux de Paris, UPMC Paris 6, France; 9Kenta Biotech, Bern,
Switzerland; 10ETH Zu¨rich, Zu¨rich, Switzerland; 11Pneumonia Clinic, University Hospital Basel, Switzerland
*Corresponding author. Professor Pierre-Franc¸ois Laterre, Intensive Care Unit, St Luc University Hospital, UCL, 10 Avenue Hippocrate, 1200 Brussels,
Belgium. Tel: +32-2-764-2735; Fax: +32-2-764-2757; E-mail: laterre@rean.ucl.ac.be
†These authors contributed equally to this work.
Received 24 November 2010; returned 18 December 2010; revised 23 January 2011; accepted 28 January 2011
Objectives: Nosocomial Pseudomonas aeruginosa pneumonia remains a major concern in critically ill patients.
We explored the potential impact of microorganism-targeted adjunctive immunotherapy in such patients.
Patients and methods: This multicentre, open pilot Phase 2a clinical trial (NCT00851435) prospectively
evaluated the safety, pharmacokinetics and potential efficacy of three doses of 1.2 mg/kg panobacumab, a
fully human monoclonal anti-lipopolysaccharide IgM, given every 72 h in 18 patients developing nosocomial
P. aeruginosa (serotype O11) pneumonia.
Results: Seventeen out of 18 patients were included in the pharmacokinetic analysis. In 13 patients receiving
three doses, the maximal concentration after the third infusion was 33.9+8.0 mg/mL, total area under the
serum concentration–time curve was 5397+1993 mg h/mL and elimination half-life was 102.3+47.8 h. Pano-
bacumab was well tolerated, induced no immunogenicity and was detected in respiratory samples. In contrast
to Acute Physiology and Chronic Health Evaluation II (APACHE II) prediction, all 13 patients receiving three
doses survived, with a mean clinical resolution in 9.0+2.7 days. Two patients suffered a recurrence at days
17 and 20.
Conclusions: These data suggest that panobacumab is safe, with a pharmacokinetic profile similar to that in
healthy volunteers. It was associated with high clinical cure and survival rates in patients developing nosoco-
mial P. aeruginosa O11 pneumonia. We concluded that these promising results warrant further trials.
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Introduction
Pseudomonas aeruginosa pneumonia is one of the most
common nosocomial infections in critically ill patients.1 – 4 The
recent emergence and spread of multidrug-resistant strains
may explain crude mortality rates as high as 40%–70%.5 – 7
The membrane-bound virulence factor lipopolysaccharide (LPS)
found on P. aeruginosa species elicits an IgM-mediated antibody
response, which is a potent activator of the complement cascade
and significantly enhances the antibacterial response. The IgM
response, however, takes several days to develop fully, a delay
that could increase the risk of death. In this context, combination
of antibiotics with specific adjunctive immunotherapy is
expected to improve the management and outcome of such
infections.
Panobacumab is a fully human monoclonal antibody of the
IgM/k isotype, which is directed against the LPS O-polysaccharide
moiety of P. aeruginosa serotype IATS O11,8,9 which accounts for
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20% of all P. aeruginosa isolates. Panobacumab demonstrated
a dose–response relationship for protection against lethal chal-
lenges with P. aeruginosa in a murine burn wound sepsis
model and protection from local infection in an acute lung infec-
tion model in mice.10 In a Phase 1 study in healthy volunteers,
single ascending doses of between 0.1 and 4 mg/kg panobacu-
mab were infused over 2 h. The study drug was safe and well tol-
erated and no immunogenicity to panobacumab was detected.
Panobacumab has shown linear pharmacokinetics, with a half-
life (mean+SD) of between 70+24 and 95+20 h, and a
volume of distribution (mean+SD) of between 4.8+1.1 and
5.5+1.0 L.11
A multicentre, open pilot Phase 2a trial was carried out to
evaluate the safety, pharmacokinetics and potential efficacy of
repeated doses of panobacumab in patients with nosocomial
pneumonia caused by P. aeruginosa serotype O11.
Patients and methods
Patients and definitions
Patients ≥18 years with nosocomial pneumonia caused by P. aeruginosa
O11 were screened for eligibility according to clinical and microbiological
criteria. Pneumonia was suspected in the presence of a new or progres-
sing pulmonary infiltrate on frontal chest radiography associated with
one of the following criteria: temperature .388C or ,368C; white blood
count .104/mm3 or ,103/mm3; purulent sputum. Diagnosis
of ventilator-associated pneumonia (VAP) further required either a
non-protected bronchoalveolar lavage (BAL) or mini-BAL positive for
P. aeruginosa ≥104 cfu/mL,2 or a protected mini-BAL positive for
P. aeruginosa ≥103 cfu/mL.12 According to recent recommendations,13
diagnosis of hospital-acquired pneumonia (HAP) further required an
endotracheal aspirate (ETA) positive for P. aeruginosa ≥106 cfu/mL and
a clinical pulmonary infection score (CPIS) of ≥6.
P. aeruginosa serotype was determined by specifically developed PCR
or by conventional microbiology/serology. Reasons for exclusion included
complement deficiency, clinically relevant liver insufficiency, dissemi-
nated intravascular coagulation, transplant-related immunosuppressive
treatment, HIV infection, septic shock with blood pressure ,90 mmHg
despite vasopressors, neutropenia and pregnancy. The study was
approved by all local ethics committees. Written informed consent was
obtained either from the patient or their next of kin prior to screening
or during the screening process according to local ethics requirements.
The study was conducted in full compliance with the principles of the
Declaration of Helsinki and in accordance with the ‘International ethical
guidelines for biomedical research involving human subjects’ as laid
down by the CIOMS in collaboration with the WHO and the GCP guideline
CPMP/ICH/135/95. The study protocol was submitted to independent
local ethics committees and approved prior to the start of the study.
Clinical trial applications were submitted to the regulatory authorities
of each country and were approved by these institutions. The study
was registered at clinicaltrials.gov under the number NCT00851435.
Procedures
Concentrations of panobacumab in serum were determined by ELISA.11
Maximal concentrations (Cmax) were measured at the end of each infu-
sion and minimal concentrations (Cmin) just before the next infusion.
The following non-compartmental pharmacokinetic (PK) parameters of
panobacumab were derived from each individual serum concentration
versus time profile using standard methods. Calculations were performed
using WinNonlin (Pharsight Corporation, version 5.2). The total area under
the curve including all three doses (AUCtotal) was calculated with the
linear trapezoidal rule for the ascending and the log-linear trapezoidal
rule for the descending parts. This was extrapolated to infinity from the
last measured concentration of the third dose [C(tn)] and the slope of
the terminal phase of the natural logarithm of the serum concentration
(lnC) versus time (t) plot (third dose). t1/2 values were estimated from the
slope of lnC versus t of the terminal linear phase (third dose), including at
least four data points. Total serum clearance (CL) was calculated from
the ratio of total dose (Dtotal) and AUCtotal, and volume of distribution
(V) from the product of CL and t1/2/ln2. Beside these calculations for indi-
vidual patients, the averaged serum concentration–time curve was fitted
with the Solver tool of Excel (MS Office 2003) to both a one- and a two-
compartment model, applying a bi- (infusion, elimination) and tri- (infu-
sion, distribution, elimination) exponential function, respectively. Both
functions were each the sum of the contributions of all three single
doses. The respective concentration contributions of the single doses
were considered as follows: Equation 1 describes the infusions over 2 h
for both models:
Cinfusion(t) = Css × (1− e(−lz×(t−t(start)))) (1)
where Cinfusion(t) is the concentration at time t during the infusion, Css is
the concentration at steady state of a constant infusion, lz is the rate
constant of the elimination phase and t(start) is t at the start of the indi-
vidual infusion. Cinfusion(t) was only considered for the duration of the
infusions. The contribution of each dose after infusion stop was calcu-
lated as shown in Equation 2 for the one-compartment model and
Equation 3 for the two-compartment model:
C(t) = Cinfusion(infusion stop) × e(−lz×(t−t(infusion stop))) (2)
C(t) = C1 × e(−l1×(t−t(infusion stop))) + Cz × e(lz×(t−t(infusion stop))) (3)
where Cinfusion(infusion stop) corresponds to Cinfusion(t) at infusion stop
(see Eq. 1) and C1 and Cz to the single contributions of the fast and term-
inal phases to Cinfusion at infusion stop, the sum of Cz and C1 equals
Cinfusion at infusion stop. Fitted parameters were Css, Cz/(Cz+C1), lz and l1.
At screening, patient medical history and underlying conditions were
noted, and physical examination, vital signs, electrocardiogram, chest
X-ray and risk factors for pneumonia recorded. Acute Physiology and
Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assess-
ment (SOFA) and CPIS scores were calculated at study entry.14 – 16 Except
APACHE II, they were assessed daily until day 30 or discharge from the
intensive care unit (ICU).
Blood samples were obtained at study entry, at panobacumab
administration and during the course of the study, for blood culture
and characterization of the inflammatory response: procalcitonin (PCT)
and C-reactive protein (CRP); for measurements of complement
level and potential immunogenicity; for PK parameters; and for haema-
tology and clinical chemistry follow-up. Respiratory samples were evalu-
ated for quantitative BAL lung bacterial burden using the reference
method17 and, in some patients, for the presence of panobacumab.
Panobacumab, 1.2 mg/kg body weight, was administered as a 2 h
infusion on days 1, 4 and 7, at the same time on each of those days.
This dose was selected based on its safety and PK profile from the
Phase 1 study and to maintain panobacumab serum concentrations in
the target population at .3 mg/mL for at least 1 week. Empirical anti-
biotic therapy was started and further modified at the discretion of the
treating physician. Patients with P. aeruginosa isolates that were non-
susceptible to empirical antibiotic therapy were considered inappropri-
ately treated. Appropriateness of antimicrobial therapy was assessed
by in vitro susceptibility.
Safety, PK and efficacy parameters were determined at various time-
points (Figure 1) up to the end of the study (day 30) or last available
assessment. Serum samples were assessed for immunogenicity to the
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study drug. BAL and ETA samples were taken according to clinical need
and were used to test for the presence of panobacumab. Samples con-
taminated with blood were excluded. The occurrence of adverse events
was monitored throughout the study.
The clinical outcome of HAP or VAP was determined by assessment of
clinical signs and symptoms as well as analysis of chest X-rays. Outcome
was reported as resolution, recurrence (relapse if caused by the same
pathogen), continuation or death during the study period.
Study profile and analysis
Figure 2 summarizes the profile of the study and subsequent analysis.
The safety population was defined as all patients enrolled in the study
who received at least one dose of study medication and who reported
at least one subsequent treatment assessment. The intent to treat
(ITT) population was defined as patients in the safety population who
had pneumonia caused by P. aeruginosa O11 and who received at least
one dose of panobacumab. The PK population was defined as all patients
with data on panobacumab serum levels in whom PK assessment could
be determined. The per protocol (PP) population was defined as patients
who completed the three study drug administrations. Efficacy analysis
was performed in the ITT and PP populations. Adverse events were
coded using the definitions of the medical dictionary for regulatory activi-
ties (MedDRA ).18 When an adverse event occurred more than once for
any patient the maximal severity and worst case causality were
counted. Assessment of immunogenicity was performed by analysing
the presence of circulating anti-idiotype antibodies to panobacumab as
previously described.11
Statistical analysis
Data management and statistical analysis were performed using SAS
version 9.2. A sample size of at least 12 patients evaluable for safety
with at least two consecutive infusions of panobacumab was considered
sufficient for this pilot Phase 2a trial. All data are presented as median
(interquartile range; IQR) unless otherwise stated.
Results
Patient demographic data and characteristics
Eighteen critically ill patients (15 VAP and 3 HAP) with con-
firmed nosocomial pneumonia caused by P. aeruginosa O11
were enrolled. A second assessment did not confirm
Pharmacokinetic (PK)
population
17 patients (15 VAP:2 HAP)
Per protocol (PP)
population
13 patients (12 VAP:1 HAP) 
Drop out: 4 patients
1 patient died
3 patients excluded after SAE 
Exclusion
1 patient excluded:
wrong serotype
Exclusion
1 patient excluded:
died, invalid for PK
analysis
Intention to treat (ITT)
population
17 patients (14 VAP:3 HAP)
Safety population (SP)
18 patients (15 VAP:3 HAP)
Figure 2. Trial profile. SAE, serious adverse event.
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Figure 1. Schedule for measurement of PK, safety and efficacy parameters. On the day of infusion of the study drug, PK and safety measurements were
performed throughout the day. The time course of these measurements is indicated by black diamonds on the time line in the lower part of the figure.
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P. aeruginosa O11 as the causative pathogen in one patient.
Baseline patient demographics and characteristics are outlined
in Table 1. All patients were under intensive care management
and reasons for ICU admission were respiratory failure (n¼7),
multiple trauma (n¼3), CNS disorders (n¼3) and miscella-
neous (n¼5).
Six patients presented a monomicrobial and 12 a polymicro-
bial pneumonia. Associated pathogens were: Serratia marcescens
(n¼2), Klebsiella pneumoniae (n¼2), Streptococcus spp. (n¼2)
and enterobacteria, Providencia rettgeri, Klebsiella oxytoca,
Staphylococcus spp., Proteus mirabilis and Escherichia coli
(n¼1). Candida spp. were cultured from the respiratory
samples of five patients.
From antibiograms collected from 16 patients, 7 P. aeruginosa
were resistant to carbapenems, 6 to ciprofloxacin, 2 to aminogly-
cosides, 3 to ceftazidime and 1 to piperacillin/tazobactam, and in
5 out of 11 cases P. aeruginosa was resistant to ticarcillin and
clavulanic acid.
Of 18 patients, 15 were initially treated with at least one of
the following antibiotics: piperacillin/tazobactam, ceftazidime,
imipenem/cilastatin, meropenem or aztreonam. Four out of
18 patients were initially given single antibiotic therapy and the
remaining patients a combination of two or more antibiotics.
Overall, aminoglycosides were administered to nine patients,
ciprofloxacin and ceftazidime to eight, nebulized colistin to one
and piperacillin plus tazobactam to four patients. Antibiotic
treatment lasted from 6 to 27 days, and its mean duration
was 12.06+5.47 days. Empirical antibiotic treatment was con-
sidered inappropriate in two patients.
Pharmacokinetics of panobacumab
Panobacumab pharmacokinetics was assessed in 17 patients (PK
population), including 13 who received three doses (PP popu-
lation). Table 2 shows detailed PK parameters in all patients.
The serum concentration–time curves of the PP population
followed either a one- (n¼3) or a two- (n¼10) compartment
model by visual inspection. While the terminal kinetic phase
was well defined in all concentration–time curves (t1/2 in
Table 3), the fast phases of the individual concentration–time
curves were not well defined. We therefore averaged the
serum concentrations of all patients in the PP population and
applied a two-compartment model fit (Figure 3). The two-
compartment model demonstrated a t1/2 in the fast phase of
10.3 h (41% of extrapolated concentration at t0). The t1/2 of
the slow phase (59% of extrapolated concentration at t0) was
90.1 h, similar to the average shown in Table 2. For comparison,
the fit with the one-compartment model resulted in a shorter
t1/2 of 58.2 h compared with the value in Table 3 and significant
deviations between the fit and the serum concentrations
(Figure 3), indicating that the two-compartment model is more
appropriate. As shown in Table 2 and Figure 3, Cmax and Cmin
(C at 72 h after infusion start) increased from the first to the
third infusion.
Panobacumab was detected in BAL and ETA samples in 4 out
of 12 patients in several samples throughout the study period
(days 3–21).
Safety
No local or systemic adverse events to the infusion of panobacu-
mab were directly reported. Electrocardiographic measurements,
including of QTc, did not show any trend relating to the study
drug (data not shown).
A total of 96 adverse events were reported in the safety
population, most of which were laboratory abnormalities
associated with the underlying disease. Four patients experi-
enced a total of eight adverse events evaluated to be poten-
tially related to panobacumab. Erythema was reported by two
patients, one of whom experienced concomitant eosinophilia.
Both cases resolved without treatment within 5 days and
both patients continued the study. One patient had evolving
cholestasis prior to study drug administration. This patient
received one dose of study drug but worsening cholestasis fol-
lowed by neutropenia and gastrointestinal bleeding precluded
further administration of panobacumab. He died on day 17
from multi-organ failure linked to this event, which was prob-
ably caused by the deterioration of his general condition. This
patient was excluded from the PP population for analysis.
Increased prothrombin time after cardiac arrest was deemed
possibly related to panobacumab and was reported by the
fourth patient. This patient also received one dose of study
drug and died on day 17 after a second cardiac arrest,
which was judged unrelated. This patient was also excluded
from the PP population.
Two other patients were excluded from the PP population after
the occurrence of a serious adverse event evaluated to be unre-
lated to panobacumab administration. One patient died on day
3 of the study due to gastrointestinal haemorrhage. One patient
was excluded from the study after suffering haemolysis due to a
mismatch in blood group antigens during a transfusion. These
two patients had received one dose of the study drug.
Eventual immunogenicity was not detected in any patient
(data not shown).
Table 1. Patient demographics and baseline characteristics
Population Safety (n¼18)
Age, median (IQR) (years) 71.5 (15.3)
Female:male 3:15
BMI, median (IQR) (kg/m2) 26.1 (4.6)
VAP:HAP 15:3
Pneumonia (polymicrobial:monomicrobial) 12:6
Empirical antibiotic therapy
(appropriate:inappropriate:NA)
14:3:1
CPIS 9.0 (1.8)
APACHE II 17.0 (4.0)
COPD 6
SOFA 6.0 (3.5)
Tracheostomy 11
Time from hospital admission to suspicion
of pneumonia/median (IQR) (days)
16.0 (14.3)
Time from ICU admission to suspicion
of pneumonia/median (IQR) (days)
9.5 (9.5)
BMI, body mass index; COPD, chronic obstructive pulmonary disease.
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Potential efficacy
Overall 30 day survival was 82% and 100% in the ITT and PP
populations, respectively (Table 3). Both populations had com-
parable APACHE II scores, but three patients in the ITT population
died, one on day 3 and two on day 17. In all cases, they had
received only one dose of panobacumab. As mentioned above
reasons for death were irreversible multi-organ failure, cardiac
arrest and massive gastrointestinal haemorrhage. Of the four
patients in the ITT population who received one dose of study
drug, none achieved clinical resolution at any time during the
study period. In contrast, all patients who received three doses
of panobacumab (PP population) did achieve clinical resolution
(time to clinical resolution 9.0+2.7 days), including two patients
who received inappropriate empirical antimicrobial therapy. Of
these patients, two experienced a recurrence 17 and 20 days
after initial resolution that was again caused by P. aeruginosa
O11. The average time from suspicion of pneumonia to panoba-
cumab administration was 1.5+0.8 days for patients who
achieved clinical resolution and did not experience a recurrence.
It was 3.5+0.7 days for the two patients with recurrence. Both
were tracheotomized without resolution of the underlying
primary reason for ICU admission at time of relapse. Five other
patients achieved clinical resolution as well as having a tra-
cheostomy. Among them, two had received inappropriate
empirical antimicrobial therapy.
The evolution of biological parameters was similar in all
groups. Patients with clinical resolution showed rapid decrease
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Figure 3. Averaged serum concentration–time curves of panobacumab.
Comparison of a one-compartment model fit (a) and a two-compartment
model fit (b). Symbols show average serum concentrations with standard
deviations; the red lines show the fitted functions.
Table 2. PK parameters of panobacumab at a dose of 1.2 mg/kg in the PP and PK populationsa
Parameter PP (n¼13)b PK (n¼17)
Body weight, kg 78.0+28.4 (53–135) 77.2+26.3 (53–135)
Cmax (1st dose, C at 2 h), mg/mL 21.2+5.0 (12.5–28.5) 21.2+5.1 (12.5–28.5)
Cmin (1st dose, C at 72 h), mg/mL 6.2+3.4 (0.14–11.5) 6.2+3.4 (0.14–11.5)
Cmax (2nd dose, C at 74 h), mg/mL 28.9+6.0 (19.9–37.6)
Cmin (2nd dose, C at 144 h), mg/mL 10.7+4.5 (3.4–16.3)
Cmax (3rd infusion, C at 146 h), mg/mL 33.9+8.0 (24.3–47.1)
C at 216 h, mg/mL 13.7+4.9 (7.6–20.4)
AUCtotal, mg h/mL 5397+1993 (2477–8600)
t1/2, h (linear terminal phase of 3rd dose) 102.3+47.8 (35.0–179.0)
Volume of distribution, L 7.5+2.8 (4.1–12.7)
Serum clearance, mL/h 57.9+21.7 (25.7–94.7)
aResults shown are mean+SD (range).
bPatients received three infusions (0–2 h, 72–74 h, 144–146 h).
Table 3. Efficacy of panobacumab in the safety, ITT, PK and PP
populations
Parameter
Safety
(n¼18)
ITT
(n¼17)
PK
(n¼17)
PP
(n¼13)
Overall patient
survival at 30 days/
end of study
15 (83.3%) 14 (82.4%) 15 (88.2%) 13 (100%)
Clinical outcome
resolution 11 (61.1%) 11 (64.7%) 11 (64.7%) 11 (84.6%)
recurrence 2 (11.1%) 2 (11.7%) 2 (11.7%) 2 (15.4%)
continuationa 5 (27.8%) 4 (23.5%) 4 (23.5%) 0 (0%)
aThree patients with continuation died, one on day 3 and two on day 17.
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in PCT and CRP values, with increase in those with clinical
continuation or recurrence.
Discussion
Panobacumab displays linear, disease-independent pharmacoki-
netics with an elimination t1/2 and a volume of distribution com-
parable to other IgM antibodies.19 Despite the severity of the
underlying inflammatory lung disease, the PK profile of panoba-
cumab, including Cmax after first infusion, serum half-life and
inter-individual variability, was close to that reported in healthy
volunteers receiving a single administration.11 The t1/2 values
of the elimination phase did not differ significantly between
the data from this study and those from the Phase 1 study.11
The fast concentration decrease starting at infusion stop
observed in most patients probably reflects the distribution of
panobacumab from serum to interstitial fluid of well-perfused
tissue. Serum panobacumab accumulation was observed over
successive administrations, raising the question of increasing
the interval between each administration in further studies. It
is not known whether panobacumab accumulation is beneficial
or not. It has to be pointed out, however, that panobacumab,
like most IgM antibodies, was well tolerated and induced
neither immunogenicity nor serious adverse effects.19 – 21
The high clinical cure, and mostly the survival rate, are in con-
trast to the severity of the enrolled population and its expected
mortality following the assessment with validated scoring
systems such as APACHE II, SOFA and CPIS. This suggests a
potential therapeutic impact of panobacumab as adjunctive
therapy; nevertheless, this open-label, Phase 2a study on the
safety and pharmacokinetics of panobacumab presents some
major limitations that may bias the interpretation of potential
efficacy. First, the population size was small. Second, in the
absence of a control group the survival benefit provided by pano-
bacumab cannot be definitively demonstrated. Eventually, the
effect of antimicrobial therapy on outcome and clinical cure
rate cannot be separated from the study drug effect. At the
time of panobacumab administration, some patients had been
receiving antibiotics for .1 day. This was due to the duration
of the screening process since the P. aeruginosa serotype O11
had to be confirmed prior to study drug administration and the
consent process. The survival rate of 100% in the group of
patients who completed the full treatment cycle may have
been biased by the exclusion of patients who died rapidly.
Finally, the current findings are restricted to serotype O11 and
not for other P. aeruginosa strains.
The incidence of pneumonia recurrence after initial infection
by P. aeruginosa ranges from 25% to 40%.22 Interestingly, in
the present study, the recurrence rate of pneumonia was also
low compared with previous studies.23 It may be due to a pro-
longed biological effect of the antigen in tissues. Detection of
an IgM monoclonal antibody in BAL and ETA samples of patients
with pneumonia was shown here for the first time. The passage
of panobacumab from the blood into the alveolar space might
partially explain its efficacy.
We conclude that these data demonstrate the safety and
favourable PK profile of panobacumab, a fully human anti-LPS
monoclonal IgM, in critically ill patients with P. aeruginosa O11
nosocomial pneumonia. Moreover, high clinical cure and survival
rates suggest potential clinical efficacy of this adjunctive immu-
notherapy, warranting further clinical trials.
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